KTTA — Pasithea Therapeutics Corp.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1841330 ·
Last close
$0.43
Market Cap
$14.51M
52W High
$2.06
52W Low
$0.28
ADV30
1,275,894
Next earnings
—
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -5,713,282 -5,273,852 51,709,945 45,663,782 1,870,258
Mar 2026 0 — -4,876,644 -2,869,482 56,354,901 50,400,377 1,542,451
Dec 2025 0 — -10,256,162 -10,110,868 60,240,070 55,158,939 5,020,832
Sep 2025 0 — -3,110,055 -3,037,420 13,630,664 4,122,953 1,423,982

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-17,781,583
Investing CF
—
Financing CF
$56,314,691
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.35
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-78,153,795
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-23,956,143
Pretax Income TTM
$-21,291,622
Interest Exp TTM
—
Analysts
1

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -20,857,295 -20,427,683 60,240,070 5,020,832 55,219,238 -15,211,490
Dec 2024 0 -14,249,962 -13,904,584 16,064,719 1,282,043 14,782,676 -13,923,438
Dec 2023 0 -15,979,361 -15,961,658 26,116,858 2,718,406 23,398,452 -13,425,411
Dec 2022 0 -12,588,971 -13,936,452 45,180,089 2,681,841 42,498,248 -13,691,158
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$5,153,685
NetIncome TTM
$-21,291,622
OpCashFlow TTM
—
Assets (Latest)
$51,709,945
Forward EPS
$-0.46

Peers — same industry

TickerNameMarket CapLastDaily %
MCRB Seres Therapeutics, Inc. $14.37M $1.41 —
BOLT Bolt Biotherapeutics, Inc. $14.73M $5.65 —
MDNAF Medicenna Therapeutics Corp. $14.77M $0.16 —
CTXR Citius Pharmaceuticals, Inc. $14.24M $0.52 —
INTI Inhibitor Therapeutics, Inc. $13.98M $0.08 —

News headlines (Yahoo Finance, 1h cache)

Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 Eur
2026-11-13 07:00 · Yahoo
Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)
2026-11-03 12:00 · Yahoo
Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026
2026-10-28 20:05 · Yahoo
Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
2026-10-23 13:15 · Yahoo
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
2026-04-20 11:01 · Yahoo
Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans?
2026-05-03 12:59 · Yahoo
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
2026-06-15 11:02 · Yahoo
Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
2026-06-10 13:55 · Yahoo
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
2026-05-04 11:01 · Yahoo
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
2026-04-01 11:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.